Wavefront Optimized Retreatment after Prior Wavefront Optimized Retreatment after Prior Wavefront Wavefront Customized Customized LASIK for Myopia LASIK for Myopia Juan C. Arciniega, MD; Engy Mohamed, MD; James P. McCulley, MD, Juan C. Arciniega, MD; Engy Mohamed, MD; James P. McCulley, MD, FRCOphth (UK); FRCOphth (UK); Wayne Bowman, MD. Wayne Bowman, MD. Department of Ophthalmology, The University of Texas Southwestern Department of Ophthalmology, The University of Texas Southwestern Medical Center at Dallas, Texas. USA. Medical Center at Dallas, Texas. USA. JCA and EM have no financial interest to disclose. JCA and EM have no financial interest to disclose. JPM and WB are consultants of Alcon Inc. JPM and WB are consultants of Alcon Inc. Financial Disclosure: Financial Disclosure: This study was supported in part by grants NIH EY12430, EY016664 and an This study was supported in part by grants NIH EY12430, EY016664 and an unrestricted grant from the Research to Prevent Blindness, New York, New unrestricted grant from the Research to Prevent Blindness, New York, New York. York.
12
Embed
Wavefront Optimized Retreatment after Prior Wavefront Customized LASIK for Myopia
Wavefront Optimized Retreatment after Prior Wavefront Customized LASIK for Myopia. Juan C. Arciniega, MD; Engy Mohamed, MD; James P. McCulley, MD, FRCOphth (UK); Wayne Bowman, MD. Department of Ophthalmology, The University of Texas Southwestern Medical Center at Dallas, Texas. USA. - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Wavefront Optimized Retreatment after Prior Wavefront Optimized Retreatment after Prior WavefrontWavefront
CustomizedCustomized LASIK for MyopiaLASIK for MyopiaJuan C. Arciniega, MD; Engy Mohamed, MD; James P. McCulley, MD, FRCOphth (UK); Juan C. Arciniega, MD; Engy Mohamed, MD; James P. McCulley, MD, FRCOphth (UK);
Wayne Bowman, MD. Wayne Bowman, MD.
Department of Ophthalmology, The University of Texas Southwestern Medical Department of Ophthalmology, The University of Texas Southwestern Medical
Center at Dallas, Texas. USA.Center at Dallas, Texas. USA.
JCA and EM have no financial interest to disclose.JCA and EM have no financial interest to disclose.
JPM and WB are consultants of Alcon Inc.JPM and WB are consultants of Alcon Inc.
Financial Disclosure:Financial Disclosure:
This study was supported in part by grants NIH EY12430, EY016664 and an unrestricted This study was supported in part by grants NIH EY12430, EY016664 and an unrestricted
grant from the Research to Prevent Blindness, New York, New York. grant from the Research to Prevent Blindness, New York, New York.
Laser in situ keratomileusis (LASIK) is a popular technique for
correcting myopia, myopic astigmatism, and mild to moderate
hypermetropia.
Although the predictability is high, undercorrection and/or regression
is inevitable in some eyes.1,2
Re-treatments may be necessary and useful to refine the results
obtained after the first surgery. 2
1) Perez-Santonja JJ, Bellot J, Claramonte P, Ismail MM, Alio JL. Laser in situ keratomileusis to correct high myopia. J Cataract Refract Surg 1997;23:372-85.
2) O’Doherty M. O’Keeffe M, Kelleher C. Five year follow-up of laser in situ keratomileusis for all levels of myopia. Br J Ophthalmol 2006;90:20-3.
BackgroundBackground
To assess the visual outcomes, refractive error, and safety of
Wavefront-Optimized (WFO) LASIK retreatment after previous
Wavefront- Customized (WFC) LASIK in myopic patients.
PurposePurpose
MethodsMethods
• A retrospective chart review of 18 eyes from 13 patients whom underwent WFO LASIK retreatment after previous WFC LASIK was performed.
• All primary LASIK procedures were done using the Visx CustomVueTM laser platform (Abbott Medical Optics, Illinois, USA).
• All eyes underwent LASIK retreatments using the Wavelight AllegrettoTM Eye-Q 400 excimer laser platform (Alcon Inc., Hünenberg, Switzerland).
• Ophthalmic examinations, including uncorrected visual acuity (UCVA), best-spectacle corrected visual acuity (BSCVA), refractive error (RE), and complications were performed preoperatively and postoperatively at 1, 3, and 6 months.
• Pre-retreatment total root mean square (RMS) from third to sixth order- Zernike polynomials was calculated.
Pre-retreatment total high order aberrations (HOA).
ResultsResults
Pre-operative and post-operative values of RE
Pre-operative POM 1 POM 3 POM 6
Spherea -0.56±1.4 -0.31±0.5 -0.24±0.36 -0.39±0.35
Range -3.0 to 1.5 -1.25 to 0.5 -1.25 to 0.25 -1.5 to 0